TREM2 and Alzheimer disease: Another study highlighted that both CSF and plasma sTREM2 levels serve as significant predictive biomarkers for progression from MCI to AD, with lower CSF TREM2 levels indicating an elevated risk of disease progression (Zhou W. et al., 2023).